PROCEPT BioRobotics stock edges lower after strong Q2 revenue growth

PROCEPT BioRobotics stock (ISIN US74271T1060) is trading around 20.91 dollars as of September 1, 2026 on Nasdaq, slightly below recent intraday levels above 21 dollars reported in market data, reflecting a modest pullback of about 1.4 percent at the last close according to Yahoo Finance.

Revenue growth remains the key driver

The San Jose based medical technology company PROCEPT BioRobotics (ISIN US74271T1060) focuses investors attention on its latest quarterly figures, with recent analysis citing annual revenue growth requirements of about 21.7 percent to support its valuation narrative and a forecasted improvement in earnings of roughly 179.4 million dollars from a current net loss of about 109.8 million dollars, according to a detailed overview on Simply Wall St.

In that same assessment, PROCEPT BioRobotics is associated with a fair value estimate around 22.73 dollars per share compared with a current market price in the low 20 dollar range, implying an upside of about 9 percent if the company can deliver the forecast growth and margin improvement highlighted by analysts at the time of publication, which frames how the stock is valued relative to its fundamentals.

Valuation, losses and investor perspective

For retail investors, the combination of strong revenue growth and ongoing losses means the path to profitability is central to the PROCEPT BioRobotics stock story, with the cited requirement for a roughly 179.4 million dollar swing in earnings underscoring how much operating leverage and margin expansion the business must achieve before net income turns positive, based on the Simply Wall St projections.

Compared with the fair value estimate of about 22.73 dollars per share, the recent closing level around 20.91 dollars as of September 1, 2026 suggests the market is currently pricing PROCEPT BioRobotics at a discount of approximately 1.82 dollars per share or about 8 to 9 percent to that analytical benchmark, a gap that could narrow or widen depending on whether upcoming quarters confirm the projected 21.7 percent annual revenue growth and the move from a net loss of 109.8 million dollars toward break even.

Transurethral therapy system as flagship product

PROCEPT BioRobotics is best known for its AquaBeam Robotic System, a minimally invasive, robot assisted waterjet therapy platform designed to treat benign prostatic hyperplasia by precisely removing prostate tissue, a procedure positioned to offer faster symptom relief and potentially fewer side effects compared with certain traditional surgical techniques according to product descriptions commonly cited by market observers.

Stock price and market data snapshot

Based on Nasdaq data compiled by Yahoo Finance, PROCEPT BioRobotics stock most recently closed at about 20.91 dollars on September 1, 2026, with intraday trading on September 2, 2026 reported around 21.12 dollars at 10:02 AM Eastern time, implying a same day gain of about 3.5 percent from that intraday snapshot according to the Yahoo Finance news and data overview.

PROCEPT BioRobotics stock at a glance

• Company: PROCEPT BioRobotics Corporation
• ISIN: US74271T1060
• Ticker: PRCT
• Trading venue: Nasdaq
• Price (as of September 1, 2026, 16:00): 20.91 USD
• Sector / Industry: Health care equipment
• Index membership: Nasdaq Composite